Indication intelligence, analysis and sector perception

Kite Pharma (KITE) Initiates enrollment for ZUMA-1 P2 in an on-going trial patients with refractory aggressive Non-Hodgkin's Lymphoma (NHL) - BUY

November 2, 2015 8:45am

KITE has opened enrollment for the P2 portion of its ongoing P1/2 clinical trial (ZUMA-1) of KTE-C19 in patients with refractory, aggressive NHL.

KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.

KITE's ZUMA-1 trial of KTE-C19 is a single arm, open-label, multi-center study, designed to determine the safety and efficacy of KTE-C19 in patients with refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL). KITE expects that the P2 portion of the trial will include a total of approximately 112 patients.

The Bottom Line: A milestone with the initiation of P2 KTE-C19 multi-center clinical trial in DLBCL. KITE should be presenting top-line data from the P1 portion of the trial at ASH and anticipates reporting interim results from the study next year.

KITE closed on 10/30 DOWN -$0.72 to $68.05 - BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 18 min ago
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation

16 hours ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.